Your browser doesn't support javascript.
loading
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.
Polyzos, Stergios A; Goulis, Dimitrios G; Giouleme, Olga; Germanidis, Georgios S; Goulas, Antonis.
Afiliação
  • Polyzos SA; First Laboratory of Pharmacology, School of Medicine, Campus of Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. spolyzos@auth.gr.
  • Goulis DG; Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Giouleme O; 2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Germanidis GS; 1st Department of Internal Medicine, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Goulas A; First Laboratory of Pharmacology, School of Medicine, Campus of Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Curr Obes Rep ; 11(3): 166-179, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35501557
PURPOSE OF REVIEW: Obesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of anti-obesity medications on NAFLD, especially focusing on hepatic histology. RECENT FINDINGS: Orlistat and some glucagon-like peptide-1 receptor analogs, including liraglutide and semaglutide, have beneficial effects on hepatic steatosis and inflammation, but not fibrosis. Other anti-obesity medications, including lorcaserin, setmelanotide, phentermine hydrochloric, phentermine/topiramate, and naltrexone/bupropion, have been minimally investigated in NAFLD. Furthermore, medications like sodium-glucose cotransporter-2 inhibitors and farnesoid X receptor have shown beneficial effects in both NAFLD and obesity, but they have not been licensed for either disease. Liraglutide, semaglutide, and orlistat may be currently used in selected patients with obesity and NAFLD. Further research is warranted, since targeting obesity may provide additional benefits on its comorbidities, including NAFLD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Antiobesidade / Hepatopatia Gordurosa não Alcoólica / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Revista: Curr Obes Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Grécia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Antiobesidade / Hepatopatia Gordurosa não Alcoólica / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Revista: Curr Obes Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Grécia